Natriuretic peptide family as a “novel candidate marker” for the assessment of diagnosis, therapeutic response and prognosis in cardiovascular disease

References (5)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Eng J Med 1998, 339: 321-8
2. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure; prognostic role of plasma brain natriuretic peptide concentrations in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16
3. Rose RA, Hatano N, Ohya S, Imalizumi Y, Giles WR. CNP activates a nonselective cation current in acutely isolated rat cardiac fibroblasts via NPR-C receptor mediated signaling. J Physiol 2007; 580: 255-74
4. Colucci W, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. For the Nesiritide study group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343: 246-53
5. Cataliotti A, Chen HH, James KD, Burnett JC. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardiovasc Med 2007; 17: 10-4.